| DC Field | Value | Language |
| dc.contributor.author | Rotaru, Ludmila | - |
| dc.contributor.author | Rotaru, Tudor | - |
| dc.date.accessioned | 2026-04-03T15:49:52Z | - |
| dc.date.available | 2026-04-03T15:49:52Z | - |
| dc.date.issued | 2026 | - |
| dc.identifier.citation | ROTARU, Ludmila and Tudor ROTARU. Lung transplantation in the management of cystic fibrosis. In: Cells and Tissues Transplantation. Actualities and Perspectives: The Materials of the National Scientific Conference with International Participation, the 4 th edition, Chisinau, March 20-21, 2026. Chișinău : CEP Medicina, 2026, p. 53. ISBN 978-9975-82-477-4 (PDF). | en_US |
| dc.identifier.isbn | 978-9975-82-477-4 | - |
| dc.identifier.uri | https://repository.usmf.md/handle/20.500.12710/33044 | - |
| dc.description.abstract | Introduction. Cystic fibrosis (CF) is an autosomal recessive genetic disorder caused by mutations in
the CFTR gene, affecting multiple organs, particularly the lungs, and leading to progressive respiratory
failure. Despite therapeutic advances, some patients progress to advanced stages of the disease, for
whom lung transplantation represents the only option with a significant impact on survival.
Materials and Methods. A narrative synthesis of specialized literature was conducted using
GeneCards, PubMed, the National Library of Medicine, and Hinari, focusing on publications from the
past 10 years.
Results. Analysis of the specialized literature indicates that lung transplantation in patients with
advanced CF leads to significant improvements in respiratory function and quality of life. Posttransplant survival is estimated at 80–90% at one year, 78–82.8% at three years, and 69–77% at five
years, while long-term survival at 10 years ranges between 50–62%, with a median of approximately
10–10.7 years. Clinical factors, including chronic infections and post-transplant rejection, influence
prognosis, whereas lung retransplantation is associated with lower survival compared to primary
transplantation, highlighting the importance of rigorous patient selection and optimal timing of
intervention. Optimization of perioperative management and personalized immunosuppressive therapy
contributes to complication reduction and improved survival. Multidisciplinary coordination of patient
management further enhances clinical outcomes and long-term survival.
Conclusions. Lung transplantation represents an essential intervention for patients with advanced CF,
significantly improving life expectancy. Rigorous perioperative management, personalized
immunosuppressive therapy, and multidisciplinary coordination contribute to the reduction of postoperative complications and improved clinical outcomes. Post-transplant risks persist, requiring
continuous monitoring and adaptive interventions. | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | CEP Medicina | en_US |
| dc.relation.ispartof | Cells and Tissues Transplantation. Actualities and Perspectives: The Materials of the National Scientific Conference with International Participation, the 4 th edition, Chisinau, March 20-21, 2026 | en_US |
| dc.subject | Cystic fibrosis | en_US |
| dc.subject | lung transplantation | en_US |
| dc.subject | post-transplant survival | en_US |
| dc.title | Lung transplantation in the management of cystic fibrosis | en_US |
| dc.type | Other | en_US |
| Appears in Collections: | Cells and Tissues Transplantation. Actualities and Perspectives: The Materials of the National Scientific Conference with International Participation, the 4 th edition, Chisinau, March 20-21, 2026
|